WuXi PharmaTech (Cayman) Inc. (ADR) logoWuXi PharmaTech (Cayman) Inc. (NYSE:WX) was upgraded by research analysts at Goldman Sachs from a “neutral” rating to a “conviction-buy” rating in a report released on Tuesday, TheFlyOnTheWall.com reports.

WuXi PharmaTech (NYSE:WX) opened at 33.88 on Tuesday. WuXi PharmaTech has a 52 week low of $26.33 and a 52 week high of $40.72. The stock has a 50-day moving average of $35.31 and a 200-day moving average of $34.52. The company has a market cap of $2.355 billion and a price-to-earnings ratio of 22.82.

WuXi PharmaTech (Cayman) Inc. (NYSE:WX) last announced its earnings results on Wednesday, August 13th. The company reported $0.49 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.47 by $0.02. The company had revenue of $163.40 million for the quarter, compared to the consensus estimate of $162.11 million. On average, analysts predict that WuXi PharmaTech will post $1.82 earnings per share for the current fiscal year.

Separately, analysts at Zacks upgraded shares of WuXi PharmaTech (Cayman) Inc. from an “underperform” rating to a “neutral” rating in a research note on Wednesday, July 16th. They now have a $33.50 price target on the stock. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.90.

WuXi PharmaTech (NYSE:WX) Inc (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People’s Republic of China and the United States.